Search results for "PARKIN"

showing 10 items of 468 documents

Protective role of heat shock proteins in Parkinson's disease.

2010

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. Despite a large amount of research, the pathogenetic mechanism of these diseases has not yet been clarified. Abnormal protein folding, oxidative stress, mitochondrial dysfunction, and apoptotic mechanisms have all been reported as causes of neurodegenerative diseases in association with neuroinflammatory mechanisms which, by generating deleterious molecules, could promote the cascade of events leading to neurodegeneration. Heat shock proteins (HSPs) play a central role in preventing protein misfolding and inhibiting apoptotic activity, and represent a class of proteins potentially involve…

Heat shock proteins Parkinson disease neuroprotective roleParkinson's diseasebiologyNeurodegenerationParkinson DiseaseDiseasemedicine.diseasemedicine.disease_causeHsp90Hsp70PathogenesisNeurologyHeat shock proteinImmunologymedicinebiology.proteinAnimalsHumansHSP70 Heat-Shock ProteinsNeurology (clinical)HSP90 Heat-Shock ProteinsNeuroscienceOxidative stressHeat-Shock ProteinsNeuro-degenerative diseases
researchProduct

Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered.

2006

The synucleinopathy known as sporadic Parkinson's disease (PD) is a multisystem disorder that severely damages predisposed nerve cell types in circumscribed regions of the human nervous system. A recent staging procedure for the inclusion body pathology associated with PD proposes that, in the brain, the pathological process (formation of proteinaceous intraneuronal Lewy bodies and Lewy neurites) begins at two sites and continues in a topographically predictable sequence in six stages, during which components of the olfactory, autonomic, limbic, and somatomotor systems become progressively involved. In stages 1 to 2, the Lewy body pathology is confined to the medulla oblongata/pontine tegme…

Inclusion BodiesPathologymedicine.medical_specialtyParkinson's diseaseLewy bodyAnatomical pathologySubstantia nigraParkinson Diseasemedicine.diseaseCentral nervous system diseaseDegenerative diseasenervous systemNeurologyForebrainmedicineTegmentumDisease ProgressionAnimalsHumansNeurology (clinical)PsychologyNeuroscienceMovement disorders : official journal of the Movement Disorder Society
researchProduct

Phenothiazines interfere with dopaminergic neurodegeneration in Caenorhabditis elegans models of Parkinson's disease

2010

Oxidative stress is involved in the pathogenesis of various neurodegenerative disorders, conventional antioxidant strategies have yet been of limited success. We have employed transgenic Caenorhabditis elegans expressing DsRed2 in dopaminergic neurons and CFP pan-neuronally, to characterize in larval and adult animals the effects of rotenone and 1-methyl-4-phenyl-pyridinium (MPP(+)) on the dopaminergic system. Investigating the antioxidant phenothiazine and different derived antipsychotic drugs, it was found that free phenothiazine exerted strong neuroprotection at the cellular level and resulted in a better performance in behavioral assays, whereas apomorphine and other dopamine agonists o…

InsecticidesApomorphineChlorpromazineDopamineBiologyPharmacologyNeuroprotectionlcsh:RC321-571Animals Genetically Modifiedchemistry.chemical_compoundAntipsychotic drugParkinsonian DisordersDopaminePhenothiazinesRotenonemedicineAnimalsHumansChlorpromazineCaenorhabditis eleganslcsh:Neurosciences. Biological psychiatry. Neuropsychiatrychemistry.chemical_classificationNeuronsDopaminergic neuronModels GeneticNeurodegenerationDopaminergicRotenonemedicine.diseaseDisease Models AnimalNeuroprotective AgentsNeurologychemistryDopamine receptorNerve DegenerationAntioxidantTricyclicmedicine.drugAntipsychotic AgentsNeurobiology of Disease
researchProduct

Neurological deficits like CVA, Trigeminal neuralgia, Post herpetic neuralgia, Meningitis, Cervical Myelopathy, Demyelinating Disease, Acoustic Neuro…

2018

Patients and methods. A total number of 35 patients with neurological deficits, like cerebrovascular accident (CVA), trigeminal neuralgia, post herpetic neuralgia, meningitis, cervical myelopathy, demyelinating disease, acoustic neuroma, muscular neuropathy and parkinsonism were treated with ozone therapy in our institution. Results. Group 1) Hemorrhagic - 6 patients Group 2) Ischemic - 29 Patients Both the groups showed improvement varying from 20% to 100%: • Hemorrhagic patients took more time for improvement as compare to ischemic group. • Hemorrhagic patients showed partial recovery. • Ischemic group showed almost 90% - 100% recovery. Patients who received ozone therapy after 12 months …

Insufflationbusiness.industrymedicine.medical_treatmentParkinsonismAcoustic neuromaOzone therapymedicine.diseaseMyelopathyTrigeminal neuralgiaAnesthesiamedicinebusinessSalineMeningitisJournal of Ozone Therapy
researchProduct

Transcranial magnetic resonance imaging-guided focused ultrasound treatment at 1.5 T: a retrospective study on treatment and patient-related paramete…

2020

Objective: To present a retrospective analysis of patient- and sonication-related parameters of a group of patients treated with a transcranial magnetic resonance imaging (MRI)-guided focused ultrasound (tcMRgFUS) system integrated with a 1.5-T MRI unit. Methods: The data obtained from 59 patients, who underwent the tcMRgFUS procedure from January 2015 to April 2019, were retrospectively reviewed for this study. The following data, among others, were mainly collected: skull density ratio (SDR), skull area (SA), number of available transducer elements (Tx), and estimated focal power at target (FP). For each of the four different treatment stages, we calculated the number of sonication proces…

Interventional magnetic resonance imagingMaterials Science (miscellaneous)medicine.medical_treatmentParkinson's diseaseEssential TremorBiophysicsGeneral Physics and Astronomy01 natural sciencesFocused ultrasound0103 physical sciencesmedicinePlane orientationInterventional Magnetic Resonance ImagingPhysical and Theoretical Chemistry010306 general physicsMathematical Physicsmedicine.diagnostic_testbusiness.industryThalamotomySettore MED/27 - NeurochirurgiaSettore MED/37 - NeuroradiologiaMagnetic resonance imagingRetrospective cohort studystereotaxic techniqueslcsh:QC1-999Settore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Parkinson Disease.essential tremor; high-intensity focused ultrasound ablation; interventional magnetic resonance imaging; Parkinson's disease; stereotaxic techniquesCoronal planeStereotaxic techniqueHigh-Intensity Focused Ultrasound AblationStereotaxic TechniqueSettore MED/26 - NeurologiaNuclear medicinebusinessSettore MED/36 - Diagnostica Per Immagini E Radioterapialcsh:Physics
researchProduct

The Impact of Depression Symptoms in Patients with Parkinson’s Disease: A Novel Case-Control Investigation

2021

Parkinson’s disease is a common neurodegenerative disease and it is known to cause motor disturbances associated with musculoskeletal problems of the locomotor apparatus, and non-motor symptoms, that are believed to have a harmful effect on health, social functioning and mobility. The aim of this study was to evaluate depression in patients with Parkinson’s Disease (PD) compared to subjects who do not have it. The sample consisted of 124 participants (mean age 69.18 ± 9.12). Patients with PD were recruited from a center of excellence for Parkinson’s disease (cases n = 62) and healthy subjects without PD from their relatives and caregivers (control n = 62). The Spanish version of Beck’s Depr…

Inventario de Depresión de Beckmedicine.medical_specialtyParkinson's diseaseHealth Toxicology and MutagenesisBeck Depression InventoryNeurocienciaslcsh:MedicineDiseasebehavioral disciplines and activitiesArticle03 medical and health sciences0302 clinical medicineInternal medicineDepresiónmedicineHumansIn patient030212 general & internal medicineDepression (differential diagnoses)Social functioningAgedbusiness.industryDepressionSignificant differencelcsh:RPublic Health Environmental and Occupational HealthHealthy subjectsBeck Depression InventoryNeurodegenerative DiseasesParkinson DiseaseMiddle Agedmedicine.diseasehumanitiesPsicologíaParkinson diseaseCaregiversbeck depression inventoryEnfermedad de ParkinsonCase-Control StudiesdepressionSistema nerviós Malaltiesbusiness030217 neurology & neurosurgery
researchProduct

Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.

2022

Background Complex parkinsonism is the commonest phenotype in late-onset PLA2G6-associated neurodegeneration. Objectives The aim of this study was to deeply characterize phenogenotypically PLA2G6-related parkinsonism in the largest cohort ever reported. Methods We report 14 new cases of PLA2G6-related parkinsonism and perform a systematic literature review. Results PLA2G6-related parkinsonism shows a fairly distinct phenotype based on 86 cases from 68 pedigrees. Young onset (median age, 23.0 years) with parkinsonism/dystonia, gait/balance, and/or psychiatric/cognitive symptoms were common presenting features. Dystonia occurred in 69.4%, pyramidal signs in 77.2%, myoclonus in 65.2%, and cere…

LevodopaPediatricsmedicine.medical_specialtyMovement disordersDeep brain stimulationGenotypemedicine.medical_treatmentPLANPLA2G6Group VI Phospholipases A2Atrophysystematic reviewParkinsonian DisordersmedicineHumansAge of OnsetparkinsonismDystoniaNBIAbusiness.industryParkinsonismmedicine.diseasenervous system diseasesPedigreeDystoniaPhenotypeNeurologyMutationCerebellar atrophyNeurology (clinical)medicine.symptomAtrophybusinessMyoclonusmedicine.drugMovement disorders : official journal of the Movement Disorder SocietyReferences
researchProduct

DCTN1 mutation analysis in Italian patients with PSP, MSA, and DLB

2020

Abstract DCTN1 encodes the largest subunit of dynactin complex essential in the retrograde axonal transport and cytoplasmic transport of vesicles; mutations in DCTN1 have been reported predominantly in individuals with Perry syndrome and, recently, in patients with progressive supranuclear palsy. Our genetic screening of DCTN1 in 79 patients with progressive supranuclear palsy, 100 patients with multiple system atrophy, and 28 patients with dementia with Lewy bodies from Italy revealed only synonymous and intronic variants, suggesting that DCTN1 mutations do not have a key role in the development of atypical parkinsonism in the Italian population.

Lewy Body DiseaseMale0301 basic medicineAgingPathologymedicine.medical_specialtyDementia with Lewy bodieDNA Mutational AnalysisDynactinProgressive supranuclear palsy03 medical and health sciences0302 clinical medicineAtrophymedicineHumansIn patientGenetic TestingGenetic Association StudiesAgedDCTN1Dementia with Lewy bodiesbusiness.industryProgressive supranuclear palsyGeneral NeuroscienceParkinson DiseaseDynactin ComplexMiddle AgedMultiple System Atrophymedicine.diseaseDCTN1030104 developmental biologyItalyMutation testingDynactinAxoplasmic transportDCTN1; Dementia with Lewy bodies; Dynactin; Multiple system atrophy; Progressive supranuclear palsyFemaleSupranuclear Palsy ProgressiveNeurology (clinical)Geriatrics and GerontologybusinessNegative Results030217 neurology & neurosurgeryDevelopmental BiologyNeurobiology of Aging
researchProduct

Nasal chemosensory tests: biomarker between dementia with Lewy bodies and Parkinson disease dementia.

2020

BACKGROUND: Dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are progressive and disabling neurodegenerative disorders, which are often misdiagnosed due to theirs overlapping clinical and paraclinical features. Nevertheless, their adequate management requires an accurate differential diagnosis. The main aim of this study was to investigate the usefulness of olfactory and trigeminal nasal testing for the differential diagnosis between DLB and PDD. METHODS: Odor thresholds to three odorants differentially activating the olfactory and trigeminal systems were assessed in patients with DLB, PDD and healthy controls (n = 20 per group). RESULTS: Odor thresholds were significant…

Lewy Body Diseasemedicine.medical_specialtyDiseasebehavioral disciplines and activitiesGastroenterologyDiagnosis Differential03 medical and health sciences0302 clinical medicineInternal medicinemental disordersmedicineDementiaHumansIn patient030223 otorhinolaryngologyCanonical discriminant analysisDetection thresholdDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesSmellOtorhinolaryngologyBiomarker (medicine)Differential diagnosisbusinessBiomarkersRhinology
researchProduct

Analysis of the LRP10 gene in patients with Parkinson's disease and dementia with Lewy bodies from Southern Italy

2020

Recently, the LRP10 gene has been associated with Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The aim of the present study was to evaluate the presence of mutations of the LRP10 gene in patients with PD or DLB from Southern Italy. Sequencing analysis revealed only 2 missense and 3 synonymous variants in patients and control subjects and a rare variant p.L622F in a PD case. These results suggest that LRP10 mutations are not a frequent cause of PD and DLB in Southern Italy.

Lewy Body Diseasemedicine.medical_specialtyNeurologyParkinson's diseaseLRP10 . Parkinson’s disease . Dementia with Lewy bodiesDermatologyDiseasebehavioral disciplines and activities03 medical and health sciences0302 clinical medicineAlzheimer DiseaseInternal medicineDementia with Lewy bodies; LRP10; Parkinson's disease.mental disordersmedicineDementiaMissense mutationHumans030212 general & internal medicineNeuroradiologyDementia with Lewy bodiesbusiness.industryParkinson DiseaseGeneral Medicinemedicine.diseasenervous system diseasesPsychiatry and Mental healthItalyMutationSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgery
researchProduct